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ABSTRACT 
Background: Enemas are used by individuals with constipation and are of- 
ten required before certain medical diagnostic procedures and surgical interven- 
tions. However, abnormalities in serum electrolyte concentrations have been 
associated with enema use. 
Objective: The aim of this study was to determine the changes in serum elec- 
trolyte concentrations (phosphorus, calcium, sodium, and potassium) and urinary 
phosphorus elimination after the administration f a sodium phosphate enema. 
Methods: Healthy volunteers aged 35 to 70 years were eligible for this open- 
label, randomized, controlled, 2-period, crossover clinical trial at the Clinical 
Research Unit of the University Hospital of Navarra, Pamplona, Spain. The 
study comprised 2one-day periods separated by a 7-day washout. All subjects 
were randomly assigned in a 1:1 ratio to 1 of 2 study sequences: (1) a single 
dose of Enema Casen ® 250 mL in the first period followed by no treatment (con- 
trol) in the second period, or (2) no treatment in the first period followed by a 
single dose of the study drug in the second period. The sequence of treatment 
was assigned using a randomization table that was prepared before the begin- 
ning of the study. Serum concentrations of phosphorus, sodium, potassium, 
and calcium were measured in both periods. Urinary phosphorus elimination 
was measured for 12 hours after enema administration (Ae0_12) in a subset of 
the subjects in the second period. Adverse events (AEs) were monitored by the 
investigators throughout the study. Normal ranges for the electrolytes were as 
follows: phosphorus, 2.5 to 5 mg/dL; calcium, 8.5 to 10.5 mg/dL; sodium, 135 to 
145 mEq/L; and potassium, 3.5 to 5 mEq/L. 
Results: Twenty-four subjects (12 men, 12 women; mean [SD] age, 47.8 
[9.6] years [range, 36-68 years]) participated in the study. All of the subjects 
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were white and none were smokers. Twelve hours after enema administration, 
mean serum phosphorus and sodium concentrat ions increased by a mean of 
1.18 mg/dL and 1.32 mEq/L, respectively (both, P < 0.001). Mean serum phos- 
phorus concentrat ions were above the upper limit of normal (5 mg/dL) at 30 
and 60 minutes after enema administration. In all subjects the values returned 
to normal within 4 hours after enema administration; a meal was provided after 
a 3-hour fast. Four subjects (16.7%) had >1 serum phosphorus concentrat ion 
measurement >7 mg/dL, a value that is considered serious hyperphosphatemia.  
A statistically significant correlation was found between phosphorus Cm~ x and 
enema retention time (r 2 = 0.452; P < 0.001). No abnormal serum concentrat ions 
were obtained for the other electrolytes measured. Phosphorus Ae0_12 was 
increased after enema administration by 86% (P < 0.001). No serious AEs were 
observed, although 13 AEs were reported in 9 subjects. None of the changes in 
serum electrolyte concentrat ions were associated with clinical symptoms. 
Conc lus ions :  Administration of an enema containing 250 mL of sodium 
phosphate was associated with serum phosphorus concentrat ions of >7 mg/dL 
in 16.7% of the healthy subjects who participated in the study; however, none 
of those subjects experienced hypocalcemia. Enema retention time was signifi- 
cantly correlated with the degree of phosphatemia. (Curr Ther Res Clin Exp. 
2006;67:334-349) Copyright © 2006 Excerpta Medica, Inc. 
Key words: phosphatemia, electrolyte modifications, odium phosphate ne- 
ma, phosphaturia,  absorption. 
INTRODUCTION 
Constipation is a common condition in the general population and occurs with 
a particularly high prevalence in elderly patients. 1 Up to 30% of healthy elderly 
individuals need chronic treatment with laxatives, and even then they might 
require the use of evacuating solutions because of fecal impaction. Evacuating 
solutions must also be administered before many diagnostic studies and surgi- 
cal interventions. Therefore, these solutions are widely used both at home and 
in medical centers. 
Generally, evacuating solutions do not contain products that have systemic 
pharmacologic effects; their mechanism of action is based on water diffusion to 
the intestinal umen by osmosis. When a saline solution is administered, the 
sodium concentrat ion i the intestinal lumen increases, resulting in an increase 
in fluids in the intestinal lumen and the detachment of fecal materials from the 
colonic mucosa. Moreover, the monosodium and disodium salts of orthophos-  
phoric acid increase peristalsis by stimulating nerve endings, resulting in the 
total elimination of stools. 2 
Enema Casen ® (Laboratorios Casen Fleet S.L., Zaragoza, Spain) is an enema 
that contains 16 g of monobasic sodium phosphate monohydrate and 3.7 g of 
sodium per 100 mL of solution. Rectal administration of the solution has been 
associated with adverse events (AEs) after a single administration, such as 
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hyperphosphatemia,  hypocalcemia, and hypernatremia, generally in patients 
with impaired renal function, hemolysis, tumor lysis syndrome, or chronic use 
of phosphorus upplements. 3 
There is little information in the l iterature (MEDLINE search without year or 
language restriction; key terms: enema AND hyperphosphatemia or enema AND 
electrolyte) about changes in serum electrolyte concentrat ions after the use of 
sodium phosphate nemas. In a double-blind study 4comparing a sodium phos- 
phate enema (n = 22) with a water enema (n = 20) and a polyethylene glycol 
electrolyte lavage solution (n = 24), a significant increase in serum phosphorus 
concentrat ion was observed in the sodium phosphate nema group compared 
with the other 2 groups, without changes in other electrolyte concentrat ions 
(P < 0.001). Serum phosphorus concentrat ions after administration of the so- 
dium phosphate nema remained within the normal range in all but 1 patient. 
The patient serum phosphorus after enema administration was 5.8 mg/dL. In an 
observational prospective study 533% of patients (5/15) had serum phosphorus 
concentrat ions that exceeded the upper limit of normal (ULN). Some other 
studies 6-1° have discussed important changes in electrolyte concentrations after 
the administration of different oral sodium phosphate preparations; however, 
due to the oral method of administration, their results cannot be extrapolated 
to enema administration. 
The small amounts of data available regarding phosphorus pharmacokinet- 
ics after rectal administration of phosphate nemas are controversial; some 
data show phosphorus modification, while others do not. There are also few 
data on the impact of phosphorus  on other electrolyte concentrat ions.  
Therefore, this was the first study designed to determine the changes in serum 
phosphorus concentrat ions after the administration of 250 mL of an enema con- 
taining sodium phosphate.  As a secondary  end point, variations in sodium, 
potassium, and calcium were determined, along with urinary phosphorus elim- 
ination for 12 hours (Ae0_12) after enema administrat ion or time 0. In addition, 
the influence of other factors (age,creatinine clearance, and enema retention time) 
on changes in electrolyte concentrat ions were assessed. 
SUBJECTS AND METHODS 
This open-label, randomized, controlled, 2-period, crossover clinical trial was 
carried out in the Clinical Research Unit of the University Hospital of Navarra, 
Pamplona, Spain. The study protocol was approved by the Clinical Research 
Ethics Committee of Navarra and the Spanish Agency of Medicines and 
Healthcare Products in 2004. The study was carried out in conformity with the 
principles of the Declaration of Helsinki 11 and the Guidelines for Good Clinical 
Practice. 12 
The individuals who were asked to volunteer for this study were existing 
patients included in a database at our research unit. The subjects were paid for 
their participation. 
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Individuals were eligible for the study if they were aged 35 to 70 years, had 
a body mass index ranging from 20 to 28 kg/m 2, were nonsmokers or smoked 
<10 cigarettes a day, had neither organic nor psychiatric illness, and were able 
to follow instructions. Each volunteer provided a medical history and under- 
went a physical examination, e lectrocardiography (ECG), and analytical testing 
(hematology, clinical chemistry, urine analysis, serum hepatitis B surface anti- 
gen, hepatitis C antibody, and human immunodeficiency antibody) prior to par- 
ticipation in the study. All subjects provided written informed consent before 
initiation of the study. 
The study comprised 2 periods. Patients were randomly assigned in a 1:1 
ratio to one of two 1-day study sequences: (1) a single dose of Enema Casen 
250 mL in the first period followed by no treatment (control) in the second period, 
or (2) no treatment in the first period followed by a single dose of the study drug 
in the second period. The sequence  of t reatment  was assigned using a ran- 
domization table that was prepared before the beginning of the study. A 7-day 
washout was established between periods. 
In both periods of the study, blood samples were extracted before and 10, 20, 
30, 40, and 60 minutes, and 2, 4, 6, and 12 hours after enema administration or 
time 0 (ie, the start time of the control period). Subjects were asked to retain 
the enema for as long as possible. Subjects fasted for 3 hours after enema ad- 
ministration or time 0. 
Urine was col lected during the following intervals: 0 to 90 minutes; 90 min- 
utes to 3 hours; 3 to 7 hours; and 7 to 12 hours after enema administrat ion or 
t ime 0. 
Normal ranges for the electrolytes were as follows: phosphorus, 2.5 to 5 mg/dL; 
calcium, 8.5 to 10.5 mg/dL; sodium, 135 to 145 mEq/L; and potassium, 3.5 to 
5 mEq/L. Serum calcium and phosphorus concentrat ions were measured using 
a colorimetric procedure. 13,14 Calcium concentrat ions were determined using 
the reagent arsenazo III (SPINREACT, S.A. Sant Esteve D'en Bas, Gerona, Spain) 
in a neutral environment, and phosphorus concentrat ions were determined in 
an acidic environment using ammonium molybdate. Urine samples were acidi- 
fied with 10% hydrochlor ic acid. These analyses were carried out in an auto- 
matic analyzer (Vitalab Viva, Dade Behring, Spankeren, The Netherlands). 
Serum potassium and sodium concentrat ions were measured using a selective 
electrode by potentiometry. These assay procedures were carried out in the 
LX-20 and CX3 automatic analyzers (Beckman Coulter, Fullerton, California). For 
all analyses, the technician responsible was blinded to the period of the study 
during which the samples were obtained. 
A number  of parameters  were calculated for the electrolytes (phosphorus,  
calcium, sodium, and potassium).  Cma x was determined when an increase 
occurred in a serum electrolyte concentrat ion after enema administrat ion or 
t ime 0. Cmh ~ was determined when a decrease occurred in a serum electrolyte 
concentrat ion after administrat ion of the solution or t ime 0. Both Tm~ and 
Tmh ~ were determined irect ly from the data. In those cases in which the 
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same values of Cma x or Cmh ~ were observed  more than once, the first occur-  
rence of the value was to be used for assessment .  The serum AUC was calcu- 
lated using the t rapezoida l  method  from enema administrat ion or t ime 0 to 
t ime t (AUCo_t), where t cor responded to each of the sampl ing times. The total 
AUC (AUC0_12) was measured until 12 hours  after administrat ion or t ime 0. 
The accumulated  phosphorus  quant i ty  in urine (Ae0_t) was determined from 
t ime 0 to t ime t. Ae0_12 was also measured.  
In both study periods, sitting blood pressure and heart  rate were recorded at 
baseline and at 30 minutes and 4 and 12 hours. At least 24 hours after the sec- 
ond period, each volunteer underwent  a final examination, which included a 
physical examination, ECG, and blood and urine analyses. 
All AEs, both those reported by the subjects and those observed by the 
investigators, were recorded. Signs of AEs were monitored cont inuously by the 
investigators. According to study protocol,  any subject  who had abnormal  
blood pressure (systolic blood pressure >140 mm Hg or diastolic blood pressure 
>90 mm Hg) or heart  rate (>100 bpm) measurements  or a cardiovascular AE was 
to undergo ECG immediately. The relationship of AEs to s tudy t reatment  was 
assessed as "not related" or "unlikely, .... possibly, .... probably," or "definitely" 
related using the Karch-Lasagna modified criteria. 15 
Statistical Analysis 
Based on a study 16 of a population similar to our subjects (mean age, 47 years; 
both sexes with creatinine clearance >70 mL/min), in whom the mean baseline 
serum phosphorus  concentrat ion was 3.56 (0.51) mg/dL, it would be necessary  
to include a minimum of 20 subjects to detect a difference of 15% in serum phos- 
phate concentrat ion at an c¢ level of 0.05 and a 1~ level of 0.90. The variabil ity of 
baseline data for calcium, sodium, and potass ium was <15%16; therefore, the 
power of the analysis was higher than 90%. 
AUC0_12 , AUC0_t, Cmax, Cmin, and the concentrat ion at each time t of each elec- 
trolyte were analyzed in relation to t reatment  using the t test for paired sam- 
pies. Phosphorus  Aeo_12 values were also compared  using the t test for inde- 
pendent  samples,  as this information was obtained only in the second period of 
the study in some subjects. 
By means of linear least squares regression analysis, the possible relation of 
enema retention time, age, and creatinine clearance with the AUCo_12 of each 
electrolyte and with the Aeo_ t of phosphorus  were explored. 
The relationship between treatment  and higher-than-normal serum electro- 
lyte concentrat ions was assessed using the Z 2 test. 
After checking the condit ions of appl icat ion of the tests  (ie, di f ferences in 
homogene i ty  for paired t test  or var iance in homogene i ty  for analysis of vari- 
ance), other  quant i tat ive data obta ined from the analyt ical  tests  and mea- 
surements  of b lood pressure  and heart  rate were analyzed using the t test  for 
matched data or analysis of var iance.  P < 0.05 was cons idered stat ist ical ly 
significant. 
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RESULTS 
Twenty-four subjects (12 men and 12 women; mean [SD] age, 47.8 [9.6] years 
[range, 36-68 years])  were included in the study (Table I). All of the subjects 
were white and were nonsmokers.  Twelve subjects were administered the 
enema in the first period, with the other 12 acting as a control; the 12 control 
subjects from the first period were administered the enema in the second 
period. 
Table II shows a significant increase in the mean Cm~ for phosphorus  and 
sodium (both, P < 0.001), and a significant decrease in the mean Cm~ n for potas- 
sium (P = 0.020) after enema administrat ion compared with the untreated 
period. The decrease in mean serum calcium concentrat ion was not significant. 
In those cases in which the same values of Cm~ and Cm~ nwere observed more 
than once, the first occurrence of the value was to be used for assessment.  This 
occurred more frequently in subjects during the untreated period than during 
the t reatment  period. The value observed under baseline condit ions was not 
found to be the maximum or minimum mean value in any of our cases. 
All of the serum phosphorus  concentrat ions were significantly higher in the 
subjects who received enemas than in the untreated subjects, except at t ime 0 
and 6 and 12 hours. Therefore, the serum phosphorus  concentrat ions were simi- 
lar at the beginning of both per iods of the s tudy and were increased for up to 
4 hours after enema administrat ion (Figure 1). The mean increase in serum 
phosphorus  concentrat ion after enema administrat ion was 1.18 mg/dL. 
Table I. Baseline demographic and clinical characteristics of 
healthy volunteers (N = 24). 
Characteristic Value 
Age, y 
Mean (SD) 47.8 (9.6) 
Range 36-68 
Weight, kg 
Mean (SD) 70.4 (13) 
Range 53-98.5 
Height, cm 
Mean (SD) 168.4 (9.6) 
Range 155-188 
BMI, kg/m 2 
Mean (SD) 24.7 (2.6) 
Range 20.2-27.9 
CICr, mL/min 
Mean (SD) 92.8 (22.2) 
Range 59.2-131.2 
BMI = body mass index; ClCr = creatinine clearance. 
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Table II. Pharmacokinetic parameters for serum concentrations of phosphorus, sodium, 
potassium, and calcium and for urinary phosphorus elimination in subjects 
administered Enema Casen ® 250 mL and those not treated (N = 24). 
Pharmacokinetic Treatment No Treatment 
Parameter Period Period P* 
Serum phosphorus 
C . . . .  mg/dL 
Mean (SD) 5.6 (1.3) 3.7 (0.5) <0.001 
Range 3.6-8.5 2.7-4.6 
Tmax, h 0.3 0.3 NS 
Range 0-2.0 0.17-2.0 
AUC0_12 , mg/dL, h 
Mean (SD) 48.9 (6.7) 42.4 (4.9) <0.001 
Range 34.4-63.4 31.8-50.3 
Serum sodium 
C . . . .  mEq/L 
Mean (SD) 141.4 (1.7) 140.2 (1.4) <0.001 
Range 138.8-146.4 137.2-143.3 
Tmax, h 0.6 0.6 NS 
Range 0.1 7-2.0 0.17-2.0 
AUC0_12 , mg/dL, h 
Mean (SD) 1682.5 (1 7.9) 1673.5 (16.0) 0.002 
Range 1655.2-1 738.2 1638.4-1 710.0 
Serum potassium 
Cmin, mEq/L 
Mean (SD) 3.7 (0.8) 3.9 (0.9) 0.02 
Range 3.64.4 3.5-4.5 
Tmin, h 0.7 0.7 NS 
Range 0-2.0 0.2-2.0 
AUC0_12 , mg/dL, h 
Mean (SD) 47.2 (2.1) 48.1 (2.6) 0.049 
Range 43.8-51.9 43.1-52.8 
Serum calcium 
Cmin, mg/dL 
Mean (SD) 8.8 (0.3) 8.7 (0.4) NS 
Range 8.3-9.4 7.4-9.2 
Tmin, h 0.7 0.5 NS 
Range 0.3-2.0 0.2-2.0 
AUC0_12 , mg/dL, h 
Mean (SD) 108.7 (3.2) 110.1 (3.7) 0.023 
Range 104.1-114.8 105.0-119.3 
Urine phosphorus t 
Aeo_12 , mg 
Mean (SD) 621.04 (151.6) 334.4 (75.1) <0.001 
Range 333.7-815.3 212.1-402.2 
AUC012 = serum concentration between 0 and 12 hours; Ae 012 = accumulated quantity of phosphorus 
in urine between 0 and 12 hours. 
*Treatment period versus untreated period. 
tData were available for only 9 subjects during the treatment sequence and 9 during the untreated 
sequence of the second period. 
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Mean (SE) serum phosphorus concentrat ions after the admin is t rat ion of 
Enema Casen ® 250 mL and w i th  no t reatment .  Solid lines indicate the serum 
phosphorus normal range. *P < 0.001 versus no t reatment ;  tp = 0.004 versus 
no t reatment .  
As a result of the serum phosphorus data obtained during the first period of 
the study, urine samples were obtained from 18 subjects during the second 
period (9 per study sequence).  This was a modification of the initial protocol 
and required the approval of the ethics committee. 
Serum phosphorus concentrat ions above the ULN (5 mg/dL) were observed 
in 14 (58.3%) of the 24 subjects between 10 minutes and 2 hours after enema 
treatment; none of the untreated subjects had abnormally high concentrat ions 
(P< 0.001). 
Mean serum phosphorus concentrat ions were above the ULN at 30, 40, and 
60 minutes after enema administration, with concentrat ions ranging from 3.4 to 
8.5 mg/dL. In the untreated period, the concentrat ions for the same period 
ranged from 2.5 to 4.2 mg/dL. The concentrat ions in the treated subjects ubse- 
quently decreased to normal in all of the subjects within 4 hours of enema 
administration. 
Four subjects had >1 serum phosphorus concentration >7 mg/dL, values con- 
sidered to be serious hyperphosphatemia. These values were isolated and limit- 
ed in time, at 40 and/or 60 minutes after enema administration. The mean (SD) re- 
tention time in these 4 subjects was significantly higher than that of the entire 
group (29 [11.7] vs 15.3 [11.5] min; P= 0.006). 
A statistically significant correlation was found between phosphorus Cm~ x
and enema retention time (r 2 = 0.452; P < 0.001) (Figure 2). Similarly, a statisti- 
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Cor re la t ion  between enema re tent ion  t ime and phosphorus  a f ter  the  ad- 
min is t ra t ion  of Enema Casen ® 250 mL. 
cally significant correlation was found between phosphorus  Tm~ and retention 
t ime (r 2 = 0.432; P < 0.001). Neither age nor creatinine clearance was correlated 
with the Tm~, Cm~, or AUC0_12 of serum phosphorus .  
Urinary phosphorus  elimination was increased for 12 hours after enema 
administrat ion (Figure 3). After enema administrat ion, phosphorus  elimina- 
tion increased by 85% in relation to the no-treatment group (P < 0.001). Only 
enema retention t ime was significantly correlated with phosphorus  Ae0_12 (P < 
0.001). 
None of the other serum electrolyte concentrat ions (ie, sodium, potassium, 
calcium) obtained during the study fell outside of the normal ranges (Table If). 
Mean serum sodium concentrat ions were significantly higher after enema 
administration than after no treatment at 30 and 60 minutes, and at 4 hours (P = 
0.031, P = 0.036, and P = 0.017, respectively) (Figure 4). No correlation was 
found between Cm~ values and retention time, age, or creatinine clearance. The 
mean increase in serum sodium concentrat ion after enema administrat ion was 
1.32 mEq/L. 
There were no significant differences in mean serum calcium concentrat ions 
between the treated and untreated subjects (Figure 5). 
Mean serum potass ium concentrat ions were significantly lower (P = 0.026) at 
40 minutes after enema administrat ion compared with the no-treatment period 
(Figure 6). 
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Figure 3. Mean (SE) accumulated quant i ty  of phosphorus e l iminated in ur ine 
throughout  the 12 hours after the admin ist rat ion of Enema Casen ® 250 mL 
and w i th  no t reatment .  
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Figure 4. Mean (SE) serum sodium concentrat ions after the admin ist rat ion of Enema 
Casen ® 250 mL and w i th  no t reatment .  *P < 0.05 versus no t reatment .  
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Figure 5. Mean (SE) serum calcium concentrations after the administration of Enema 
Casen ® 250 mL and wi th  no treatment.  *P < 0.05 versus no treatment.  
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Figure 6. Mean (SE) serum potassium concentrations after the administration of 
Enema Casen ® 250 mL and with no treatment. *P< 0.05 versus no treatment. 
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No serious AEs were observed, although 13 AEs were reported in 9 subjects 
(Table llI). The severity of the AEs was assessed as mild in each case. None of 
the subjects had abnormal vital signs (blood pressure and heart rate), and no 
patients underwent ECG because of AEs. Medical treatment was necessary  for 
2 episodes of headache (treated with paracetamol and ibuprofen) and 1 episode 
of back pain (treated with topical diclofenac). The remainder of the AEs did not 
require treatment because the subjects recovered spontaneously. The results of 
the analysis of the blood samples drawn the day after the last period showed 
some values outside of the reference range, but none of these abnormal values 
had clinical consequences.  No clinically significant changes were observed in 
physical examination findings, ECG properties, blood pressure, heart rate, res- 
piratory rate, or temperature. 
DISCUSSION 
The results of this study suggest hat after the administration of Enema Casen 
250 mL, phosphorus and sodium were absorbed systemically, so that mean 
serum phosphorus concentrat ion was increased by 1.18 mg/dL and mean 
serum sodium concentrat ion was increased by 1.32 mEq/L. In a 2006 observa- 
tional prospect ive study, 5 15 patients, mean aged 73 years, were administered 
2 or 3 Enema Casen 250 mL enemas the night prior to colonoscopy. All the 
patients had higher serum phosphorus concentrat ions after enema administra- 
tion (0.9 mg/dL of difference, P = 0.002), although the time the final blood sam- 
ple was obtained was not reported. It is possible that serum concentrat ions 
measured in the first hour after enema administration would have been higher 
and more similar to our observations. 
Table III. Reported adverse events (AEs) and their relationship to the study medication. 
AEs occurred in 1 subject unless otherwise noted. 
Relation to the Study Medication AE 
Not related Headache (3 subjects) 
Allergic stigmas and asthenia 
Back pain 
Hematochezia 
Right submandibular adenopathy 
Slight increase in transaminase activities 
Dizziness 
Headache 
Abdominal cramping 
Abdominal pain and sensation of coldness 
Sensation of coldness and general malaise 
Unlikely 
Probable 
Possible 
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Our results might ave smaller changes than those observed after the admin- 
istration of other sodium phosphate  laxative products  because those products  
were administered orally. 17 Also, the quantity of electrolytes in the oral prod- 
ucts is higher than that in the rectal products,  18 and rectal absorpt ion might be 
more erratic than absorpt ion via other routes. 19 In our study, the serum phos- 
phorus concentrat ions of 58% of the subjects were above normal  values at 30, 
40, and 60 minutes after enema administration. This increase was self-limited, 
because phosphorus  ur inary elimination after enema administrat ion was 85% 
greater than that observed in the untreated period. This higher ur inary elimina- 
tion made accumulat ion of phosphorus  impossible in blood up to 6 hours after 
administration. 
Enema retention t ime in the intestinal lumen was a decisive factor in the 
increase in phosphorus  Tm~, as has been suggested in previous studies. 2°,21 
During our study the subjects were asked to prolong the enema retention t ime 
as much as possible. According to the product  description, 2 Enema Casen usu- 
ally works in 2 to 5 minutes. The retention time was extended in this s tudy to 
assess what occurs  when the enema does not cause the desirable effect and 
therefore, it was not expelled and remained in the bowel more than desirable. 
In our s tudy population, the high serum phosphorus  concentrat ions might have 
been physiological ly regulated by an increase in renal elimination of phospho-  
rus, as observed by others. 22 The increases in serum phosphorus  concentra- 
tion and the renal elimination of phosphorus  we observed were not correlated 
with age, as descr ibed previously, 23 or with creatinine clearance (probably  be- 
cause our volunteers had values up to 25 mL/min). 21 
The serum calcium concentrat ions did not change significantly during the 
12-hour study period in the treated subjects, with all values remaining within 
the normal range. In a prospect ive study, 5 serum calcium concentrat ions were 
below the lower limit of normal in 27% of cases; however, those patients 
received 2 or 3 enemas. Cases of toxicity that have been descr ibed have gener- 
ally been a result of decreases in serum calcium concentrat ion,  somet imes with 
fatal outcomes.  2~4° In these cases, the nemas might have been administered 
to ill patients, children, or patients with moderate  to severe renal or hepatic fail- 
ure. The package insert indicates that the enema is contraindicated in such 
patients or should be used with caution. 2During this s tudy no changes in serum 
calcium concentrat ions were observed,  suggesting that the phosphatemia  ob- 
served  during the s tudy  was not clinically re levant because  it was not asso- 
ciated with hypocalcemia.  
Because serum concentrat ions of sodium and potass ium remained within 
the normal range throughout  he study, they were considered clinically irrele- 
vant. The enemas were general ly well to lerated in this populat ion of healthy 
subjects.  
A limitation of this s tudy was that it might not be possible to generalize the 
findings to a wider patient population. The study was conducted in healthy sub- 
jects, while most  AEs associated with enema use occur in patients with under- 
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lying medical  problems.  3 However, while several  studies have examined 
changes in serum concentrat ions with sodium phosphate  preparat ions admin- 
istered orally, 6-1°,17 little data are available regarding the effects of enemas on 
serum electrolyte concentrat ions in healthy subjects or individuals with health 
problems. In an at tempt o make the results appl icable to a wider population, 
subjects as old as 70 years were eligible for the study, because age is one of the 
predictors of hyperphosphatemia  after the use of oral sodium phosphate  
preparat ions.  16 
CONCLUSIONS 
The administrat ion of a 250 mL enema containing sodium phosphate  was asso- 
ciated with serum phosphorus  concentrat ions ~7 mg/dL in 16.7% of the healthy 
subjects who part ic ipated in the study; however, none of those subjects expe- 
r ienced hypocalcemia.  Enema retention time was significantly correlated with 
the degree of phosphatemia  observed.  
ACKNOWLEDGMENT 
This s tudy was suppor ted  
(Zaragoza, Spain). 
by grants from Laborator ios Casen Fleet S.L. 
REFERENCES 
1. Martinez Velasco MC, Ahmad al Ghool M, Sos Ortigosa F, Bengoechea Barcala C. 
Acute hyperphosphatemia induced by enemas [in Spanish]. Med Clin (Barc). 1998; 
110:805. 
2. Enema Casen [package insert]. Zaragoza, Spain: Laboratorios Casen Fleet S.L.; 2004. 
3. Shiber JR, Mattu A. Serum phosphate abnormalities in the emergency department. 
J Emerg Med. 2002;23:395-400. 
4. Cohan CF, Kadakia SC, Kadakia AS. Serum electrolyte, mineral, and blood pH changes 
after phosphate nema, water enema, and electrolyte lavage solution enema for flexi- 
ble sigmoidoscopy. Gastrointest Endosc. 1992;38:575-578. 
5. Gutierrez-Santiago M, Garcia-Unzueta M, Amado JA, et al. Electrolyte disorders fol- 
lowing colonic cleansing for imaging studies [in Spanish]. Med Clin (Barc). 2006; 
126:161-164. 
6. Ainley E J, Winwood P J, Begley JP. Measurement ofserum electrolytes and phosphate 
after sodium phosphate colonoscopy bowel preparation: An evaluation. Dig Dis Sci. 
2005;50:1319-1323. 
7. Ell C, Fischbach W, Keller R, et al, for the Hintertux Study Group. A randomized, 
blinded, prospective trial to compare the safety and efficacy of three bowel-cleansing 
solutions for colonoscopy (HSG-01*). Endoscopy. 2003;35:300-304. 
8. Seinela L, Pehkonen E, Laasanen T, Ahvenainen J. Bowel preparation for colonoscopy 
in very old patients: A randomized prospective trial comparing oral sodium phos- 
phate and polyethylene glycol electrolyte lavage solution. Scand J Gastroenterol. 
2003;38:216-220. 
347 
CURRENT THERAPEUTIC RESEARCH 
9. Poon CM, Lee DW, Mak SK, et al. Two liters of polyethylene glycol-electrolyte lavage 
solution versus sodium phosphate as bowel cleansing regimen for colonoscopy: A 
prospective randomized controlled trial. Endoscopy. 2002;34:560-563. 
10. Mathus-Vliegen EM, Kemble UM. A prospective randomized blinded comparison of 
sodium phosphate and polyethylene glycol-electrolyte solution for safe bowel 
cleansing. Aliment Pharmacol Ther. 2006;23:543-552. 
11. World Medical Association Declaration of Helsinki: Recommendations Guiding 
Medical Doctors in Biomedical Research Involving Human Subjects [WMA Web site]. 
Ferney-Voltaire, France: WMA; 1989. Available at: http://www.wma.net. Accessed 
June 18, 2004. 
12. European Agency for the Evaluation of Medicinal Products, International Conference 
on Harmonisation-World Health Organization. Guideline for Good Clinical Practice 
[EMEA Web site]. ICH Topic E6. Geneva, Switzerland: WHO; 2002. Available at: 
http://www.emea.eu.int. Accessed June 18, 2004. 
13. Calcio Arsenazo III. Colorimetric [in Spanish]. Available at: ht p://www.spinreact.com/ 
uploads/pdf/BSDTT09%20CALCIUM-A%20III.pdf. Accessed October 13, 2006. 
14. Fosforo. Fosfomobildato. Colorimetric [in Spanish]. Available at: http://www.spinreact. 
com/uploads/pdf/BSDTT15%20PHOSPHORUS%20-UV.pdf. Accessed October 13, 2006. 
15. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. 
Clin Pharmacol Ther. 1977;21:247-254. 
16. Gumurdulu Y, Serin E, Ozer B, et al. Age as a predictor of hyperphosphatemia after 
oral phosphosoda administration for colon preparation. J Gastroenterol Hepatol. 
2004; 19:68-72. 
17. Curran MP, Plosker GL. Oral sodium phosphate solution: A review of its use as a colo- 
rectal cleanser. Drugs. 2004;64:1697-1714. 
18. Tan HL, Liew QY, Loo S, Hawkins R. Severe hyperphosphataemia andassociated elec- 
trolyte and metabolic derangement following the administration f sodium phos- 
phate for bowel preparation. Anaesthesia. 2002;57:478-483. 
19. van Hoogdalem E J, de Boer AG, Breimer DD. Pharmacokinetics of rectal drug admin- 
istration, part II. Clinical applications of peripherally acting drugs, and conclusions. 
Clin Pharmacokinet. 1991;21:110-128. 
20. Schuchmann GD, Barcia PJ. Phosphate absorption from fleet enemas in adults. Curr 
Surg. 1989;46:120-122. 
21. Gutierrez E, Gonzalez E, Hernandez E, et al. Acute hyperphosphatemia secondary to 
phosphate administration for bowel preparation [in Spanish]. Nefrologia. 2004;24: 
283-287. 
22. Grosskopf I, Graff E, Charach G, et al. Hyperphosphataemia and hypocalcaemia 
induced by hypertonic phosphate nema--an experimental study and review of the 
literature. Hum Exp Toxicol. 1991;10:351-355. 
23. Marin Gabriel JC, Rodriguez Munoz S, de la Cruz Bertolo J, et al. Electrolytic distur- 
bances and colonoscopy: Bowel lavage solutions, age and procedure. Rev Esp 
Enferm Dig. 2003;95:863-875. 
24. Nir-Paz R, Cohen R, Haviv YS. Acute hyperphosphatemia caused by sodium phos- 
phate enema in a patient with liver dysfunction and chronic renal failure. Ren Fail. 
1999;21:541-544. 
25. Soumoy MP, Bachy A. Risk of phosphate nemas in the infant [in French]. Arch 
Pediatr. 1998;5:1221-1223. 
348 
B. S/ldaba et al. 
26. Helikson MA, Parham WA, Tobias JD. Hypocalcemia and hyperphosphatemia after 
phosphate nema use in a child. J Pediatr Surg. 1997;32:1244-1246. 
27. Ehrenpreis ED, Wieland JM, Cabral J, et al. Symptomatic hypocalcemia, hypomagne- 
semia, and hyperphosphatemia secondary to Fleet's Phospho-Soda co]onoscopy 
preparation i a patient with a jejunoilea] bypass. Dig Dis Sci. 1997;42:858-860. 
28. Sutters M, Gaboury CL, Bennett WM. Severe hyperphosphatemia and hypocalcemia: 
A dilemma in patient management. JAm Soc Nephrol. 1996;7:2056-2061. 
29. Wilmanns C, Bernschneider T, Schoffel U, Farthmann EH. Enema-induced hyperphos- 
phatemia in ileus of the small and large intestine [in German]. Zentralbl Chir. 
1995;120:981-983. 
30. Fass R, Do S, Hixson LJ. Fatal hyperphosphatemia following Fleet Phospo-Soda in a 
patient with colonic ileus. Am J Gastroenterol. 1993;88:929-932. 
31. Korzets A, Dicker D, Chaimoff C, Zevin D. Life-threatening hyperphosphatemia and 
hypocalcemic tetany following the use of fleet enemas. J Am Geriatr Soc. 1992;40: 
620-621. 
32. Wason S, Tiller T, Cunha C. Severe hyperphosphatemia, hypocalcemia, cidosis, and 
shock in a 5-month-old child following the administration f an adult Fleet enema. 
Ann Emerg Med. 1989;18:696-700. 
33. Biberstein M, Parker BA. Enema-induced hyperphosphatemia. Am J Med. 1985;79: 
645-646. 
34. Rohack J J, Mehta BR, Subramanyam K. Hyperphosphatemia and hypocalcemic coma 
associated with phosphate nema. South Med J. 1985;78:1241-1242. 
35. Reedy JC, Zwiren GT. Enema-induced hypocalcemia and hyperphosphatemia leading 
to cardiac arrest during induction of anesthesia in an outpatient surgery center. 
Anesthesiology. 1983;59:578-579. 
36. Haldimann B, Vogt K. Hyperphosphatemia and tetany following phosphate enema [in 
French]. Schweiz Med Wochenschr. 1983;113:1231-1233. 
37. Sotos JF, Cutler EA, Finkel MA, Doody D. Hypocalcemic coma following two pediatric 
phosphate nemas. Pediatrics. 1977;60:305-307. 
38. Davis RF, Eichner JM, Bleyer WA, Okamoto G. Hypocalcemia, hyperphosphatemia, 
and dehydration following a single hypertonic phosphate nema. JPediatr. 1977;90: 
484-485. 
39. Martin RR, Lisehora GR, Braxton M Jr, Barcia PJ. Fatal poisoning from sodium phos- 
phate enema. Case report and experimental study. JAMA. 1987;257:2190-2192. 
40. Ma KK, Ng CS, Mui LM, et al. Severe hyperphosphatemia andhypocalcemia following 
sodium phosphate bowel preparation: A forgotten menace. Endoscopy. 2003;35:717. 
Address correspondence to: Bel6n S~daba, MD, PhD, Servicio de Farmacologia 
CHnica, Clinica Universitaria de Navarra, 36 Avda. de Pio XII, 31008 Pamplona, 
Spain. E-mail: bsadaba@unav.es 
349 
